From: B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review
Stable disease | n | Age Mean ± SD | FEV1 | FEV1 % Pred | Smoking current/past/never | Exacer-bation definition | % LVSD or HF (EF) | Renal function | AF % | NP (pg/ml) | NP levels mean ± SD/SE* or median (IQR) | Controls mean ± SD or median (IQR) P value vs COPD | NP levels subgroups mean ± SD or median (IQR) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fujii [71] | 21 | 68 ± 5 | 0.94 | 45 | nr | - | ex | normal | nr | BNP | 8 ± 2* | - | - |
Cabanes [72] | 17 | 65 ± 6 | 1.3 | nr | nr | - | ex | nr | exc | BNP | 14 ± 12 | - | - |
Hemlin [73] | 25 | 66 ± 1 | 0.8 | 34 | 28/72/0 | - | ex | normal | exc | BNP | 21 ± 5* | - | - |
Papaioannou [74] | 49 | 66 ± 9 | nr | 42 | 49/nr/nr | - | ex | nr | exc | BNP | 31 (15–70) | - | - |
Kim [75] | 22 | 73 ± 6 | nr | 46 | nr | - | nr | nr | nr | BNP | 41 ± 60 | - | - |
Anderson [17] | 93 | 68 ± 2 | nr | 70 | 34/66/0 | - | 1 (<40%) | nr | nr | BNP | 29 ± 6* | 26 (20–32) p = 0.46 | - |
Gemici [18] | 17 | 53 ± 11 | nr | 55 | nr | - | ex | normal | nr | BNP | 21 ± 16 | 13 ± 11 p > 0.05 | - |
Rutten [24] | 200 | 73 ± 5 | nr | 84 | nr | - | 15 (≤45%) | nr | 9 | BNP | 39 (17–79) | - | LVSD 135 (41–317), p < 0.001 |
Rutten [24] | 200 | 73 ± 5 | nr | 84 | nr | - | 15 (≤45%) | nr | 9 | NT–BNP | 117 (72–210) | - | LVSD 560 (169–1572), p < 0.001 |
Watz [30] | 170 | 64 ± 7 | nr | 56 | 42/nr/nr | - | 3 (≤50%) | nr | nr | NT–BNP | 67 (40–117) | - | - |
Murphy [76] | 25 | 66 ± 9 | 0.95 | 40 | 88/12/0 | - | 12 (<55%) | exc renal failure | nr | NT–BNP | 113 (147) | - | LVSD 296, p = 0.01 |
Gale [25] | 140 | 67 ± 13 | 1.2 | nr | 82/11/6 | - | 11 (<45%) | Cr mean 92 μmol/l | 9 | NT–BNP | 44 ± 132 | - | LVSD 537 (119–2243), p = 0.03 |
Macchia [26] | 218 | 70 ± 70 | 1.25 | 39 | 24/72/4 | - | 14 (≤40%) | 5% renal failure | nr | NT–BNP | 103 (49–273) | - | LVD 677 (384–1682), p < 0.0001 |
Patel [40] | 118 | 68 ± 9 | 1.22 | 49 | 36/nr/nr | - | nr | nr | nr | NT–BNP | 12 (6–21) | - |  |
Boschetto [21] | 23 | 69 ± 4 | nr | 78 | nr | - | ex | eGFR mean 66 | nr | NT–BNP | 121 (59–227) | 50 (43–51) p = ns | - |
Wang [22] | 80 | 70 ± 6 | nr | nr | nr | - | ex | eGFR mean 73 | nr | NT–BNP | 245 (196–336) | 101 (56–150) | - |
Rubinsztajn [77] | 81 | 65 ± 7 | nr | 52 | nr | - | nr | nr | nr | NT–BNP | 190 ± 234 | - | - |
Sanchez [78] | 71 | 65 ± 7 | nr | 39 | 10/90/0 | - | ex | nr | exc | NT–BNP | 79 ± 70 | - | - |
Beghe [23] | 70 | 69 ± 8 | nr | 60 | nr | - | ex | nr | nr | NT–BNP | 115 (50–364) | 50 (43–51) p < 0.05 | - |
Ozdemirel [19] | 31 | 61 ± 8 | 1.60 | 57 | 39/55/6 | - | ex | exc renal failure | exc | NT–BNP | 100 ± 82 | 48 (35) p = 0.003 |  |
Bando [27] | 14 | 75 ± 1 | 1.09 | 57 | nr | - | nr | exc renal failure | nr | BNP | 13 ± 3* | 7 ± 1 | CP 81 ± 13, p < 0.001 |
Bozkanat [28] | 38 | 59 ± 7 | nr | 40 | nr | - | ex | nr | nr | BNP | 21 ± 10 | 9 ± 3 | CP 74 ± 36, p < 0.001 |
Anar [29] | 80 | nr | nr | 32 | nr | - | nr | exc renal failure | nr | NT–BNP | 58 ± 64 | - | CP 869 ± 1135, p < 0.001 |
Coldea [79] | 72 | 59 ± 7 | 1.8 | nr | 69/nr/nr | - | ex | eGFR median 57 | nr | NT–BNP | 204 (69–311) | - | CP 1323 (234–2567), p < 0.001 |
Exacerbation | |||||||||||||
Xie [80] | 174 | 72 ± 6 | nr | 47 | nr | Hospital | nr | nr | nr | BNP | 254 (100–521) | 7 (5–10) | - |
Escande [81] | 29 | 66 ± 10 | nr | 37 | 27/nr/nr | Hospital | ex | eGFR median 92 | exc | BNP | 37 (21–78) | - | - |
Gariani [47] | 57 | 76 ± 8 | nr | nr | nr | Hospital | 23 (<50%) | nr | 28 | BNP | 420 ± 426 | - | - |
Abroug [46] | 148 | 68 [15] | nr | nr | nr | ICU | 18 (<50%) | Cr med 93 μmol/l | nr | NT–BNP | 398 (673) | - | HF 5374 (8243), p < 0.0001 |
Martins [82] | 149 | 77 ± 11 | nr | nr | nr | Hospital | 51 HF | 17% renal failure | 37 | NT–BNP | 268 (482) | - | - |
Marteles [83] | 99 | 74 ± 8 | nr | nr | nr | Hospital | ex | exc renal failure | nr | NT–BNP | 1289 ± 1875 | - | - |
Chang [44] | 244 | 72 ± 11 | 0.81 | 35 | 33/63/3 | Hospital | ex | 9% renal failure | nr | NT–BNP | 243 ± 498 | - | - |
Hoiseth [45] | 99 | 72 ± 9 | 0.91 | 33 | nr | Hospital | 14 HF | Cr med 65 μmol/l | 10 | NT–BNP | 423 (264–909) |  | HF 1554, p = 0.102 |
Ouanes [43] | 120 | 67 [15] | nr | nr | nr | ICU | 17 LVSD | 58% renal failure | nr | NT–BNP | 3796 ± 5448 |  | LVD 3313 (4603), p < 0.001 |
Akpinar [41] | 172 | 71 ± 10 | 1.50 | 56 | nr | Hospital | nr | exc renal failure | nr | NT–BNP | 1188 ± 3233 |  |  |
Exacerbation vs Stable Control | |||||||||||||
Kanat [31] | 30 | 65 ± 7 | nr | 67 | nr | Hospital | ex | exc renal failure | nr | BNP | 405 (184–2108) | 101 (63–342) p = 0.0001 | RVD 1460 (857–3018), p = 0.01 |
Wang [32] | 311 | 75 | nr | nr | nr | ED | 16 (<45%) | eGFR median 73 | 9 | NT–BNP | 840 (248–3334) | 208 (187–318) | HF 4828 (2044–9204), p < 0.001 |
Exacerbation vs Stable Phase | |||||||||||||
Stolz [33] | 208 | 70 ± 10 | 0.93 | 41 | 45/47/8 | ED | 10 | 8% renal failure | nr | BNP | 65 (34–189) | 45 (25–85) p < 0.001 | CM 144 (58–269), p < 0.001 |
Inoue [35] | 60 | nr | nr | nr | nr | Mixed | 6 (<50%) | nr | nr | BNP | 80 ± 16* | 41 ± 9 p = 0.004 |  |
Nishimura [36] | 61 | 75 ± 8 | nr | 81 | nr | Hospital | 6 (<50%) | nr | nr | BNP | 55 (27–129) | 18 (10–45) p < 0.0001 |  |
Lee [37] | 18 | 71 | 0.8 | 36 | nr | Hospital | 28 LVSD | exc renal failure | nr | NT–BNP | 630 (220–2500) | 147 (7–980) p = 0.04 |  |
Patel [38] | 98 | 72 ± 8 | 1.14 | 52 | 20/nr/nr | Antibiotics ± steroids | nr | nr | nr | NT–BNP | 36 ± 57 | 23 ± 39 p < 0.001 |  |
El Mallawany [39] | 20 | 58 ± 9 | nr | nr | nr/nr/25 | ICU | 20 LVSD | nr | nr | NT–BNP | 1298 ± 849 | 539 ± 485 p = 0.03 | HF: 6777 ± 1434 |